Divi’s Q2 FY27 Profit Jumps 64% as Revenue Hits ₹3,676 Crore
Divi’s Laboratories reported a 63.6% rise in Q2 FY27 consolidated profit to ₹1,127 crore as revenue from operations grew 35.4% to ₹3,676 crore.
Divi’s Laboratories reported a 63.6% rise in Q2 FY27 consolidated profit to ₹1,127 crore as revenue from operations grew 35.4% to ₹3,676 crore.
AstraZeneca Pharma India will launch Datverzo for HR-positive, HER2-negative breast cancer in November 2026 as Q2 FY27 revenue rose 30% to ₹729 crore.
Aurobindo Pharma’s Q2 FY27 net profit rose 32.5% to ₹1,124 crore as revenue hit a record ₹10,263 crore on US and Europe growth and 12 USFDA approvals.
Aarti Drugs’ Q2 FY27 net profit rose 83% to ₹82.8 crore as revenue grew 27% to ₹828.8 crore and the EBITDA margin hit a near six-year high of 16.6%.
Lupin’s Q2 FY27 sales rose 14% to ₹7,785.5 crore, but net profit fell 22% to ₹1,155.3 crore as its EBITDA margin narrowed 770 basis points to 27.9%.
Evonile Pharma, formerly Novartis India, posted Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore as it builds its own field force.
Neuland Labs’ Q2 FY27 profit fell 47% to ₹51.1 crore as income slipped 11%, while the API maker opened a new peptide plant and bought land in Kakinada.
Granules India’s Q2 FY27 net profit rose 39% to ₹182 crore on 20% revenue growth, with three first-to-file ANDAs and five US launches lined up.
Akums Q2 FY27 profit rose 168% to ₹115 crore as revenue grew 31.9% to ₹1,342 crore and its CDMO business, now 83% of sales, grew 38.6%.
Wockhardt Miqnaf access widens after DCGI lifted a supply condition on the novel antibiotic, as Q2 FY27 revenue rose 24% to ₹969 crore on biotech growth.
Sun Pharma’s Q2 FY27 revenue rose 11.9% to ₹16,198.7 crore on a 17.3% jump in India formulations, while US sales fell 8.3% and a one-time loss pulled reported profit down 32%.
Alivus Life Sciences (formerly Glenmark Life Sciences) posted Q2 FY27 revenue of Rs 682 crore, up 16%, and PAT of Rs 197 crore, up 51.3%. Non-Glenmark sales rose 20.8% to 79% of revenue, CDMO revenue grew about 80% to Rs 50 crore, and Solapur Phase 1 goes live in Q3 FY27.
Strides Pharma Science grew Q2 FY27 revenue 17% to ₹1,429.7 crore. Ex-US markets rose 31% to ₹696 crore, passing the US business (₹686 crore, +9%) in quarterly revenue for the first time, while EBITDA crossed ₹250 crore and margins eased to 17.6%.